Navigation Links
Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Date:1/3/2012

SAN DIEGO, Jan. 3, 2012 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the 30th Annual J.P. Morgan Healthcare Conference in San Francisco on Monday, January 9, 2012 at 5:00 p.m. ET / 2:00 p.m. PT. Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, will provide a corporate overview.

The presentation and break-out session will be webcast through the "Investors" section of Amylin's corporate website at www.amylin.com, and a recording will be made available following the event. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California and has a commercial manufacturing facility in Ohio. Further information about Amylin Pharmaceuticals is available at www.amylin.com.


'/>"/>
SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Amylin and Lilly Set Date and Time for Conference Call
2. Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA
3. Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
4. Amylin Pharmaceuticals to Webcast Third Quarter Results
5. Amylin Pharmaceuticals Reports Third Quarter Financial Results
6. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
7. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
8. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
9. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
10. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
11. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... AxioMx Inc. , a ... Institutes of Health (NIH) has awarded the company a Phase I Small Business ... Institute of Diabetes and Digestive and Kidney Diseases. AxioMx will use this award ...
(Date:9/1/2015)... ... September 01, 2015 , ... Knowledgent , the data and analytics ... advanced analytics utilizing data lakes in the healthcare industry. , As the Internet of ... of data over the last few years as more entities become technology enabled through ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... from University of California Los Angeles, Boston University School of Medicine, Frederick National ... in PLOS One, the world’s first multidisciplinary Open Access journal. , Christopher ...
(Date:8/31/2015)... GUELPH, ON , Aug. 31, 2015 /PRNewswire/ - BIOREM ... new orders totalling $5.7 million. The orders are for air emission ... "Of particular note is a large order for a ... our equipment will be replacing a competitor,s system that failed ... see in our engineered solutions," said Derek S. Webb ...
Breaking Biology Technology:AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 2AxioMx Announces Receipt of SBIR Grant for DNA-Protein Complex Antigen Development 3New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3
... Warhol, who once said everyone will be famous for 15 minutes, ... 2.0 might have on his prediction. , ,With these tools, everyone ... not even that. It seems that 15 minutes is about all ... chamber of Silicon Valley. , ,I was reminded of this ...
... - Pre-clinical toxicology data indicates that the lead cancer drug ... important preconditions set by the Food and Drug Aministration ... which was presented at the annual meeting of the ... can be manufactured on a large scale and applied in ...
... Wis . - Mithridion, Inc ., a biopharmaceutical start ... Alzheimer's disease, has closed an additional $1.2 million of Series ... ,The latest round of funding brings the total equity capital ... the company's initial funding target. Mithridion will use the funds ...
Cached Biology Technology:On the Web, attention spans shrink, the need for value rises 2On the Web, attention spans shrink, the need for value rises 3Quintessence Biosciences advances cancer drug 2Alzheimer's drug developer lands $1.2M in venture funding 2Alzheimer's drug developer lands $1.2M in venture funding 3
(Date:8/12/2015)... , Aug. 12, 2015   MedNet Solutions , ... entire spectrum of clinical research, is proud to announce ... company,s comprehensive SaaS-based eClinical technology platform, has led the ... first two quarters of 2015.   Q2 2015 and ... quarters measured by contract value sold in the company,s ...
(Date:8/10/2015)... Germany , August 10, 2015 ... in Eye Tracking Technology for more than two decades, ... Platform for integration into all consumer display formats. The ... seamless integration of eye tracking into consumer tablets, laptops, ... reality smart glasses. Omnivision,s leading sensor technology contributes to ...
(Date:8/5/2015)... , August 5, 2015 According ... Access Management Market by Software, Services, Vertical (BFSI, Airport, IT ... Geography - Global Forecast to 2020", published by MarketsandMarkets, ... Market globally into various segments. The global PIAM Market ... to $546.2 Million by 2019, at a CAGR of ...
Breaking Biology News(10 mins):MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 2Physical Identity and Access Management Market Worth $546.2 Million by 2019 3Physical Identity and Access Management Market Worth $546.2 Million by 2019 4
... have long known that epidemics of dengue fever wax ... they've never been quite sure why. With the incidence ... understanding the factors that influence these epidemics has never ... at the University of Georgia suggests that a brief ...
... researcher at the San Francisco VA Medical Center will ... Kazakhstan, this Saturday, Sept. 2, 2006, to prepare a ... is suppressed in the weightless environment of space. , ... Growth at SFVAMC, scientific advisor to the Under Secretary ...
... company Biosignal Ltd and the Institute for Eye Research ... trial of an antibacterial extended-wear contact lens. , The ... UNSW researchers at the Centre for Marine Biofouling and ... will compare the safety performance of an antibacterial contact ...
Cached Biology News:UGA study explains peaks and troughs of dengue epidemics 2UGA study explains peaks and troughs of dengue epidemics 3Scientist-astronaut sends T-cells into space 2Scientist-astronaut sends T-cells into space 3First human trial of antibacterial contact lens 2
This antibody detects an ~92 kDa protein corresponding to the apparent molecular mass of the beta subunit of Hypoxia Inducible Factor-1 (HIF-1beta) on Western blots....
Complexin-1/2 (FL-134)...
...
... (human, porcine) Endogenous potent vasoconstrictor ... receptor and modulates vascular tonus. ET-1, ET-2, ... distinct endothelin genes. ET-2 and ET-3 are ... and six amino acids, respectively. All three ...
Biology Products: